相关实验视频
Updated: Jul 17, 2026

09:12
MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
一个基因选将PITX1识别为RAS活性和瘤性抑制剂
Ingrid G M Kolfschoten1, Bart van Leeuwen, Katrien Berns
1Division of Tumor Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Cell
|June 18, 2005
概括
通过抑制RAS通路,PITX1作为瘤抑制剂起作用. 低PITX1表达与癌症相关,恢复它可以减少瘤的生长,揭示了癌症发展的新机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 激活RAS突变驱动瘤发生,但许多癌症具有野生类型的RAS,这表明了其他激活机制.
- 识别新的瘤抑制基因对于理解癌症的发展和找到新的治疗点至关重要.
研究的目的:
- 为了确定参与癌症发展的新型瘤抑制基因.
- 研究PITX1在RAS通路调节和瘤发生中的作用.
主要方法:
- 选了RNA干扰库的基因,这些基因的淘汰将人类原始细胞转化为无瘤性RAS.
- 在人类瘤和癌症细胞系中评估PITX1表达.
- 在结肠癌细胞中恢复了PITX1的表达,并评估了它对瘤发生性的影响.
- 确定RASAL1是PITX1.1的一个转录标.
主要成果:
- 确定了PITX1作为一种新的瘤抑制基因.
- 抑制PITX1激活了RAS通路,并促进了瘤发生性.
- 在前列腺,膀瘤和野生型RAS结肠癌细胞系中观察到低PITX1表达.
- 恢复PITX1以野生类型RAS依赖的方式抑制瘤发生性.
- 通过对RASAL1.1的转录调节,PITX1降低了RAS通路的调节.
结论:
- 通过RASAL1.1,PITX1通过降低RAS通路的调节来起到瘤抑制作用.
- PITX1-RASAL1轴的调节失调可能会导致野生型RAS.在癌症的瘤发生.
相关概念视频
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

